The first mechanism involves enhanced GSK3β/β-TrCP-dependent degradation of NRF2 through activation of the AMPK/mTOR signaling pathway, and thereby triggering ferroptosis selectively in lung cancer cells. The gene discussed is MTOR; the disease is lung carcinoma.